Association of lipoprotein a combined with triglyceride-glucose index and in-hospital outcomes in patients with stemi undergoing percutaneous coronary intervention

Background: Mortality and morbidity caused by coronary heart disease are among the highest globally. This study aimed In an attempt to ascertain if the triglycerides-glucose index (TyG index) and in-hospital outcomes in patients having percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction correlate with lipoprotein a (Lp(a)) Methods: This prospective observational cohort study included 100 patients admitted with STEMI and undergoing PCI at Sharm El Sheikh international hospital and Benha University Hospital. The level of Lp (a) was used to categorize patients into two groups: Out of the total number of participants, 71 were assigned to the low Lp(a) group (< 30 mg/dL), whereas 29 were assigned to the high Lp(a) group (≥ 30 mg/dL). The levels of the TyG index were classified into two categories: For group I, there were 74 participants with a TyG index level more than 8, and for group II, there were 26 participants with a TyG index level between 4 and 6. Results: The only significant predictors for the incidence of in-hospital heart failure, according to the multivariate logistic regression analysis, were age, hypertension, Killip classification, fasting blood sugar (FBS), Lp(a), triglycerides (TYG), ejection fraction (EF), and coronary artery dissection. The only significant predictors for the occurrence of in-hospital major arrhythmia, according the multivariate logistic regression analysis, were diabetes mellitus, Killip classification, FBS, Lp(a), TYG, EF, and contrast volume. Killip classification, Lp(a), TYG, EF, and the wall motion score index were the only variables that were shown to be significant predictors of mortality occurrence in the multivariate logistic regression analysis. Conclusion: Patients with ST-elevation myocardial infarction (STEMI) may be treated with individualized plans using the TyG index and Lp(a) to identify those at risk for in-hospital major adverse cardiac events (MACE) after PCI.